Synergistic Honokiol and MCP Anti-Inflammatory Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory treatments often have significant side effects and do not effectively address excessive inflammation across all tissues, as they may not work well together and can magnify side effects when co-administered, highlighting the need for agents that reduce inflammation through different pathways without interfering with each other.
Innovation Solution
The co-administration of honokiol and modified citrus pectin (MCP) in a synergistic ratio, which inhibit inflammation through distinct pathways, including binding to Gal-3 to reduce fibrosis and inflammation, and modulating signaling molecules to suppress pro-inflammatory cytokines and growth factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory treatments are co-administered to address excessive inflammation, then the anti-inflammatory effect is improved, but the side effects are magnified and the treatments may interfere with each other
Solution Approach 1:
The patent combines honokiol and modified citrus pectin (MCP) into a single synergistic formulation that addresses inflammation through multiple pathways simultaneously. This merging of two distinct anti-inflammatory agents with different mechanisms of action allows for enhanced therapeutic effect while avoiding the negative interactions that occur when conventional anti-inflammatory drugs are co-administered
Solution Approach 2:
The invention creates a composite therapeutic system comprising honokiol and MCP in specific ratios. This composite approach leverages the complementary properties of both agents - honokiol's ability to modulate signaling molecules and suppress pro-inflammatory cytokines, combined with MCP's capacity to bind Gal-3 and reduce fibrosis - to achieve superior anti-inflammatory activity with minimized side effects
2Ease of operation
If single anti-inflammatory agents are used to treat inflammation, then the treatment is simple, but the effectiveness is limited and does not address multiple inflammatory pathways
Solution Approach 1:
The honokiol-MCP combination serves multiple functions simultaneously: it suppresses pro-inflammatory cytokines through honokiol's signaling modulation, binds Gal-3 to reduce fibrosis through MCP's specific binding capacity, and addresses inflammation across multiple tissues and disease states. This multi-functionality is achieved within a single treatment regimen, maintaining simplicity while dramatically improving effectiveness
Solution Approach 2:
The patent merges two agents with complementary mechanisms into a unified therapeutic approach that addresses multiple inflammatory pathways concurrently. This combination allows the treatment to function as both a cytokine suppressor and a fibrosis inhibitor, providing comprehensive anti-inflammatory coverage without requiring multiple separate treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination achieves a synergistic effect in reducing inflammation, potentially offering greater benefits than either agent alone while minimizing side effects, applicable for various inflammatory conditions, including cancer, autoimmune diseases, and cardiovascular diseases.
Implementation Method 1
binding to Gal-3 to reduce fibrosis and inflammation
Implementation Method 2
modulating signaling molecules to suppress pro-inflammatory cytokines and growth factors
Data Source
AI summary
A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents. The inflammation may be manifested as gingivitis, which may be addressed by a preparation comprising honokiol and MCP, or an MCP equivalent, in the indicated range by weight, where they are in the form of an oral rinse, lozenge, sucking candy, toothpaste or tablet.